Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

47.10 +1.46 (+3.20%)
Streaming Delayed Price Updated: 12:18 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday. 
Via Benzinga
Analyst Expectations for Guardant Health's Future
Via Benzinga
The Latest Analyst Ratings for Guardant Health
Via Benzinga
Preview: Guardant Health's Earnings
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Bull Of The Day: NeoGenomics
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
The Latest Analyst Ratings for Guardant Health
Via Benzinga
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
This company's fight against a deadly disease could pay off. 
Via The Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
The oncology diagnostic companies are looking for better solutions in early cancer diagnosis. 
Via The Motley Fool
Why Guardant Health Stock Jumped 15% This Week
The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know. 
Via The Motley Fool
Why Guardant Health Stock Popped Again Today
Wall Street loves this unprofitable biotech. 
Via The Motley Fool
Analyst Ratings for Guardant Health
Via Benzinga
Why Shares of Guardant Health Jumped This Week
The cancer diagnostic company saw its shares take a big jump for the second straight week. 
Via The Motley Fool
What 11 Analyst Ratings Have To Say About Guardant Health
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Guardant Health Earnings Perspective: Return On Capital Employed
Via Benzinga
Looking Into Guardant Health's Return On Capital Employed
Via Benzinga
2 Cathie Wood Stocks to Buy and Hold for 10 Years
These companies' growth stories still have plenty of exciting chapters ahead. 
Via The Motley Fool
Guardant Health Stock Sees Renewed Technical Strength
Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85. 
Via Investor's Business Daily
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023
Via Benzinga
Guardant Health Shares Move Lower On $350M Public Offering: The Details
Guardant Health Inc (NASDAQ: GH) shares are trading lower Tuesday after the company announced an offering.  
Via Benzinga
Why Guardant Health's Shares Climbed This Week
The company, which focuses on oncology screenings, saw a big gain in revenue in the first quarter. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle
The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell. 
Via Investor's Business Daily
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
Investing now is an admittedly risky bet, but the payoff could be massive. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.